Celldex Therapeutics, Inc.

Celldex Therapeutics develops antibody drugs that work against severe inflammatory and allergic diseases. The company's main drug candidate, Barzolvolimab, is designed to treat chronic skin conditions like hives and itchy nodules on the skin. Another candidate, CDX-622, targets inflammation by blocking proteins and reducing mast cells, which are immune cells that trigger allergic reactions. The company is testing these drugs in patients to see if they work better than existing treatments.